RxDoctor Payments Data

Shannon Coleman

Family · Pensacola, FLNPI 1326504374

Payments from drug & device makers

$388in general payments, 2019–2025

Across 16 payments — averaging $24.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$138
  • Otsuka America Pharmaceutical, Inc.$54
  • Smith+Nephew$48
  • Neurocrine Biosciences, Inc.$39
  • Lilly USA, LLC$30
  • Avanir Pharmaceuticals, Inc.$19
  • plus $59 from 4 others

What the payments were for

  • Food & beverage$388100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$388 in reported general payments places this provider in the 50th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$195,538
Medicare patients
356
Services billed
2,863

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban298$93,829
IngrezzaValbenazine Tosylate12$44,477
TrulicityDulaglutide93$33,763
JardianceEmpagliflozin72$22,423
AptiomEslicarbazepine Acetate17$21,365
NuedextaDextromethorphan Hbr/Quinidine50$20,301
LinzessLinaclotide34$19,524
Tiotropium Bromide24$11,468
Atorvastatin Calcium570$10,679
Stiolto RespimatTiotropium Br/Olodaterol Hcl20$10,301
XareltoRivaroxaban32$10,124
EntrestoSacubitril/Valsartan26$8,697
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$8,426
Omega-3 Acid Ethyl Esters55$6,876
JanuviaSitagliptin Phosphate24$6,870

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$39$44,47712 claims
Lilly USA, LLCTrulicity, Olanzapine$30$35,898147 claims
Avanir Pharmaceuticals, Inc.Nuedexta$19$20,30150 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 14,618 family providers in Florida.

Other family in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →